An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.

Coppieters G, Deventer K, Polet M, Van Eenoo P, Judák P

Journal of pharmaceutical and biomedical analysis12 Mar 2022Cited by 3 (Europe PMC)

PMID35298973DOI10.1016/j.jpba.2022.114726PepBankPUB-35298973

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01LabNot a test of CJC-1295 (with DAC) aloneOther designOther
An ultrafiltration nanoLC-HRMS/MS method for GHRH analogues including CJC‑1295 reached limits of detection of 5 to 25 pg/mL and limits of identification of 25 to 50 pg/mL.
In plain wordsIn lab tests, a urine method could detect CJC‑1295 and related peptides at very low levels.
Peptide
CJC-1295 (with DAC)
Outcome
Not applicableLimits of detection and identification in urine
Study
n: not reported in source
Urine samples
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOD
5 to 25 pg/mL
ultrafiltration nanoLC-HRMS/MS
LOI
25 to 50 pg/mL
ultrafiltration nanoLC-HRMS/MS
Source sentences
Summary
Even in the absence of immuno-affinity purification steps, high sensitivity was still ensured as limits of detection between 5 and 25 pg/mL and limits of identification between 25 and 50 pg/mL were established.
In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking CJC-1295 (with DAC).
Report a problemFND-3529897301
02LabNot a test of CJC-1295 (with DAC) aloneOther designOther
Compared with immuno-affinity purification, ultrafiltration gave higher recoveries and similar sensitivity for GHRH analogues including CJC‑1295.
In plain wordsIn lab tests, the simple ultrafiltration step recovered CJC‑1295 and related peptides better than antibody extraction, with similar sensitivity.
Peptide
CJC-1295 (with DAC)
Outcome
Not applicableRecovery compared with immuno-affinity purification
Study
n: not reported in source
Urine samples
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Recovery
59 to 115%
ultrafiltration
Source sentences
Summary
In a comparison with immuno-affinity purification, enhanced recoveries (59 - 115%) and similar sensitivity were achieved, yet at lower operational costs.
In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking CJC-1295 (with DAC).
Report a problemFND-3529897302
03LabNot a test of CJC-1295 (with DAC) aloneOther designOther
Stability experiments showed that urine handling matters to avoid degradation of the GHRH peptide hormones, which includes CJC‑1295.
In plain wordsIn lab tests, urine samples need careful handling to stop peptides such as CJC‑1295 from breaking down.
Peptide
CJC-1295 (with DAC)
Outcome
Not applicableStability in urine
Study
n: not reported in source
Urine samples
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
Stability experiments showed the importance of the proper handling of urine samples to avoid degradation of these peptide hormones, especially for sermorelin and its metabolite which were found to rapidly degrade at temperatures > 4 °C and pH values < 7 in accordance with earlier studies.
In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking CJC-1295 (with DAC).
Report a problemFND-3529897303
04LabNot a test of Tesamorelin aloneOther designOther
An ultrafiltration nanoLC-HRMS/MS method for GHRH analogues including tesamorelin reached limits of detection of 5 to 25 pg/mL and limits of identification of 25 to 50 pg/mL.
In plain wordsIn lab tests, a urine method could detect tesamorelin and related peptides at very low levels.
Peptide
Tesamorelin
Outcome
Not applicableLimits of detection and identification in urine
Study
n: not reported in source
Urine samples
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOD
5 to 25 pg/mL
ultrafiltration nanoLC-HRMS/MS
LOI
25 to 50 pg/mL
ultrafiltration nanoLC-HRMS/MS
Source sentences
Summary
Even in the absence of immuno-affinity purification steps, high sensitivity was still ensured as limits of detection between 5 and 25 pg/mL and limits of identification between 25 and 50 pg/mL were established.
In this study, Tesamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesamorelin.
Report a problemFND-3529897304
05LabNot a test of Tesamorelin aloneOther designOther
Compared with immuno-affinity purification, ultrafiltration gave higher recoveries and similar sensitivity for GHRH analogues including tesamorelin.
In plain wordsIn lab tests, the simple ultrafiltration step recovered tesamorelin and related peptides better than antibody extraction, with similar sensitivity.
Peptide
Tesamorelin
Outcome
Not applicableRecovery compared with immuno-affinity purification
Study
n: not reported in source
Urine samples
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Recovery
59 to 115%
ultrafiltration
Source sentences
Summary
In a comparison with immuno-affinity purification, enhanced recoveries (59 - 115%) and similar sensitivity were achieved, yet at lower operational costs.
In this study, Tesamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesamorelin.
Report a problemFND-3529897305
06LabNot a test of Tesamorelin aloneOther designOther
Stability experiments showed that urine handling matters to avoid degradation of the GHRH peptide hormones, which includes tesamorelin.
In plain wordsIn lab tests, urine samples need careful handling to stop peptides such as tesamorelin from breaking down.
Peptide
Tesamorelin
Outcome
Not applicableStability in urine
Study
n: not reported in source
Urine samples
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
Stability experiments showed the importance of the proper handling of urine samples to avoid degradation of these peptide hormones, especially for sermorelin and its metabolite which were found to rapidly degrade at temperatures > 4 °C and pH values < 7 in accordance with earlier studies.
In this study, Tesamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesamorelin.
Report a problemFND-3529897306
07LabNot a test of Sermorelin aloneOther designOther
An ultrafiltration-based nanoLC-HRMS/MS assay for GHRH analogs including sermorelin in urine had limits of detection between 5 and 25 pg/mL.
In plain wordsA lab method detected sermorelin and related peptides in urine at 5 to 25 pg/mL.
Peptide
Sermorelin
Outcome
Not applicableLimit of detection in urine
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOD
5 to 25 pg/mL
GHRH analogs in urine
Source sentences
Summary
limits of detection between 5 and 25 pg/mL and limits of identification between 25 and 50 pg/mL were established.
1 context sentence(design, population, supporting numbers)
Summary · context
This work presents an ultrafiltration-based, validated method for the screening and confirmation of prohibited growth hormone-releasing hormone (GHRH) analogues (sermorelin/CJC-1293, sermorelin metabolite, CJC-1295 and tesamorelin) in urine by nanoLC-HRMS/MS.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-3529897307
08LabNot a test of Sermorelin aloneOther designOther
The assay had limits of identification between 25 and 50 pg/mL for GHRH analogs including sermorelin in urine.
In plain wordsThe lab method could confirm the identity of sermorelin and related peptides in urine at 25 to 50 pg/mL.
Peptide
Sermorelin
Outcome
Not applicableLimit of identification in urine
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOI
25 to 50 pg/mL
GHRH analogs in urine
Source sentences
Summary
limits of identification between 25 and 50 pg/mL were established.
1 context sentence(design, population, supporting numbers)
Summary · context
This work presents an ultrafiltration-based, validated method for the screening and confirmation of prohibited growth hormone-releasing hormone (GHRH) analogues (sermorelin/CJC-1293, sermorelin metabolite, CJC-1295 and tesamorelin) in urine by nanoLC-HRMS/MS.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-3529897308
09LabNot a test of Sermorelin aloneOther designOther
Compared with immuno-affinity purification, the ultrafiltration assay gave enhanced recoveries of 59-115% and similar sensitivity at lower operational costs.
In plain wordsThe ultrafiltration lab method recovered more of the peptides than the antibody-based method and was as sensitive, at lower cost.
Peptide
Sermorelin
Outcome
Not applicableRecovery and sensitivity versus immuno-affinity purification
Study
n: not reported in source
Comparator
Immuno-affinity purification
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Recovery
59 to 115%
GHRH analogs
Source sentences
Summary
In a comparison with immuno-affinity purification, enhanced recoveries (59 - 115%) and similar sensitivity were achieved, yet at lower operational costs.
1 context sentence(design, population, supporting numbers)
Summary · context
This work presents an ultrafiltration-based, validated method for the screening and confirmation of prohibited growth hormone-releasing hormone (GHRH) analogues (sermorelin/CJC-1293, sermorelin metabolite, CJC-1295 and tesamorelin) in urine by nanoLC-HRMS/MS.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-3529897309
10LabNot a test of Sermorelin aloneOther designOther
Sermorelin and its metabolite degraded rapidly in urine at temperatures above 4 degrees C and pH values below 7.
In plain wordsIn lab tests, sermorelin in urine broke down quickly when warmer than 4 degrees C or at pH below 7.
Peptide
Sermorelin
Outcome
Not applicableStability of sermorelin in urine
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
Stability experiments showed the importance of the proper handling of urine samples to avoid degradation of these peptide hormones, especially for sermorelin and its metabolite which were found to rapidly degrade at temperatures > 4 °C and pH values < 7 in accordance with earlier studies.
1 context sentence(design, population, supporting numbers)
Summary · context
This work presents an ultrafiltration-based, validated method for the screening and confirmation of prohibited growth hormone-releasing hormone (GHRH) analogues (sermorelin/CJC-1293, sermorelin metabolite, CJC-1295 and tesamorelin) in urine by nanoLC-HRMS/MS.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-3529897310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 39Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Versions 2 to 3
9 Oct 2026, 03:13 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:13 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.